Zelapar, Hycamtin

Chia sẻ: Nguyen Uyen | Ngày: | Loại File: PDF | Số trang:4

Thêm vào BST

Báo xấu

53
lượt xem 4
download

Download Vui lòng tải xuống để xem tài liệu đầy đủ

Zelapar trị Parkinson, dùng chung với ledopa/carbidopa, - Hycamtin với Cistaplin trị ung thư tử cung giai đoạn IV-B, - Fluoroxetine trị bệnh Anorexia nervosa (biếng ăn tâm thần), - FDA bỏ Canasa 500mg nhưng vẫn cho dùng thuốc nhét Canasa 1000mg, Nexavar trong việc điều trị ung thư gan di căn, Nexavar cũng cho dùng điều trị ung thư thận trầm trọng, - Myvax chữa ung thư máu trong việc điều trị miễn dịch ung thư máu Follicular non-Hogkin lymphoma. - Ngoài ra FDA cũng cho phép thử nghiệm Panitumumab trong việc dùng kháng thể tạo sinh từ...

Chủ đề:

Bình luận(0) Đăng nhập để gửi bình luận!

Lưu

Nội dung Text: Zelapar, Hycamtin

Zelapar, Hycamtin - Zelapar trị Parkinson, dùng chung với ledopa/carbidopa, - Hycamtin với Cistaplin trị ung thư tử cung giai đoạn IV-B, - Fluoroxetine trị bệnh Anorexia nervosa (biếng ăn tâm thần), - FDA bỏ Canasa 500mg nhưng vẫn cho dùng thuốc nhét Canasa 1000mg, Nexavar trong việc điều trị ung thư gan di căn, Nexavar cũng cho dùng điều trị ung thư thận trầm trọng, - Myvax chữa ung thư máu trong việc điều trị miễn dịch ung thư máu Follicular non-Hogkin lymphoma. - Ngoài ra FDA cũng cho phép thử nghiệ m Panitumumab trong việc dùng kháng thể tạo sinh từ người, tác dụng yếu tố thụ thể biểu bì tăng trưởng. New Parkinson Disease Treatment Approved
The FDA has approved Valeant Pharmaceuticals’once-daily Zelapar (selegiline HCl) orally disintegrating tablets as adjunct therapy for Parkinson disease patients being treated with levodopa/carbidopa who demonstrate deterioration in their response to therapy. Zelapar has been shown to reduce “off” time an average of 2.2 hours per day using Zydis technology, which allows the tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose. Expanded Indication Approved for Hycamtin The FDA has approved GlaxoSmithKline’s Hycamtin (topotecan HCl) in combination with cisplatin for the treat ment of stage IV-B, recurrent, or persistent carcinoma of the cervix that is not amenable to treatment with surgery and/or radiation therapy. Fluoxetine Use in Recovering Anorexia Nervosa Patients A study published in the JAMA evaluated fluoxetine in treating patients with anorexia nervosa following weight restoration. The randomized, double-blind, placebo-controlled trial compared 49 patients with anorexia nervosa who received fluoxetine with 44 patients taking placebo for up to 1 year as outpatients. Similar percentages of patients
assigned to fluoxetine and placebo maintained a body mass index of at least 18.5 and remained in the study for 52 weeks (P = 0.57) with no significant difference observed between fluoxetine and placebo in time-to-relapse. Canasa 500 mg Suppository Discontinued Axcan Scandipharm has discontinued its Canasa (mesalamine) 500 mg suppository. Canasa will still be available as a 1,000 mg suppository, indicated for the treatment of active ulcerative proctitis. Fast Track Status Granted for Nexavar The FDA has granted fast track status to Bayer Pharmaceuticals and Onyx Pharmaceuticals’ Nexavar (sorafenib) tablets for the treatment of metastatic hepatocellular carcinoma. Nexavar is approved for the treatment of advanced renal cell carcinoma. Fast Track Status Granted for MyVax The FDA has granted fast track status to Genitope Corporation’s MyVax, a personalized immunotherapy for the treatment of follicular non- Hodgkin lymphoma (fNHL). Priority Review Granted for Panitumumab
The FDA has accepted the BLA and granted priority review for Amgen’s panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor. The BLA was submitted for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy, including oxaliplatin- and/or irinotecan-containing regimens. Ds Trịnh Nguyễn Ðàm Giang